Associated tags: Thalassemia, Pharmaceutical industry, Patient, PDE9, Sickle cell disease, Therapy, Heart failure, Heart failure with preserved ejection fraction, COVID-19, Security (finance), SCD, HBF, Fetal hemoglobin, NFE2L2, Development, Inflammation, Hemoglobinopathy, VOC, Society
Locations: NEW YORK, BOSTON, UNITED STATES, MA, US, REDWOOD CITY, CA, NY, NEW YORK CITY, NORTH AMERICA, LOUISIANA
Retrieved on:
Wednesday, February 22, 2023
Telephone,
Therapy,
Cancer,
Annual report,
Prospectus,
Plan,
Form,
Computershare,
Internet,
Risk,
Patient,
CUSIP,
Exercise,
Sumathi Best Television Current Reporting Award,
Agreement,
Nature,
Sale,
Communication,
Book,
Security (finance),
Imara,
Mergers and acquisitions BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara’s stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara’s common stock to the stockholders of Enliven Therapeutics, Inc. (“Enliven”) pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the “Merger”).
Key Points:
- At the special meeting, Imara’s stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara’s common stock to the stockholders of Enliven Therapeutics, Inc. (“Enliven”) pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into Enliven, with Enliven surviving the merger as a wholly-owned subsidiary of Imara (the “Merger”).
- In addition, Imara today announced that it will effect a 1-for-4 reverse stock split of its common stock that will be effective on Thursday, February 23, 2023, prior to the closing of the Merger.
- The new CUSIP number for the combined company’s common stock following the Merger and the reverse stock split is 29337E 102.
- Immediately prior to the reverse stock split, Imara will have 400 million authorized shares due to Imara’s receipt of stockholder approval to increase the number of its authorized shares from 200 million to 400 million.
Retrieved on:
Thursday, October 13, 2022
Boulder, CO and Boston, MA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) (Imara) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
Key Points:
- Boulder, CO and Boston, MA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. (Nasdaq: IMRA) (Imara) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
- We are excited to announce this merger with Imara, which comes at a pivotal moment for Enliven.
- Under the terms of the merger agreement, Imara will issue to pre-merger Enliven stockholders shares of Imara common stock as merger consideration in exchange for the cancellation of shares of capital stock of Enliven and Enliven will become a wholly-owned subsidiary of Imara.
- In connection with the proposed transaction between Imara and Enliven, Imara intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus of Imara and information statement of Enliven.
CGMP,
Company,
Vomiting,
Risk,
Blood,
Forte,
Biomarker,
Safety,
Headache,
Population,
Therapy,
Private Securities Litigation Reform Act,
Clinical trial,
Thalassemia,
Adult,
PDE9,
Fetal hemoglobin,
HB,
Dizziness,
Volatile organic compound,
U.S. Securities and Exchange Commission,
Nausea,
HBF,
TDT,
SCD,
VOC,
Goal,
ITT,
Nasdaq,
COVID-19,
GLOBE,
Sickle cell disease,
Annual report,
Ardent,
Heart failure,
Patient,
Security (finance),
Pharmaceutical industry,
Imara,
NFE2L2,
Heart failure with preserved ejection fraction BOSTON, April 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) today announced results from interim analyses of its Ardent Phase 2b clinical trial of tovinontrine (IMR-687) in patients with sickle cell disease (SCD) and Forte Phase 2b clinical trial of tovinontrine in patients with beta-thalassemia. Imara also announced that because of the data generated by these interim analyses, the company will discontinue the Ardent and Forte trials as well as the further development of tovinontrine in sickle cell disease and beta-thalassemia.
Key Points:
- BOSTON, April 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) today announced results from interim analyses of its Ardent Phase 2b clinical trial of tovinontrine (IMR-687) in patients with sickle cell disease (SCD) and Forte Phase 2b clinical trial of tovinontrine in patients with beta-thalassemia.
- Imara also announced that because of the data generated by these interim analyses, the company will discontinue the Ardent and Forte trials as well as the further development of tovinontrine in sickle cell disease and beta-thalassemia.
- Ardent Phase 2b Sickle Cell Disease Interim Analysis:
The interim analysis for the Ardent trial was conducted when all participants completed the week 24 assessment or terminated early.
- The Forte study was a randomized, double-blind, placebo-controlled, multicenter Phase 2b clinical trial evaluating the safety and tolerability of tovinontrine in adult patients with beta-thalassemia.
Research,
Development,
HBF,
SCD,
OLE,
Week,
Goal,
VOC,
U.S. Securities and Exchange Commission,
Commencement,
Sickle cell disease,
Thalassemia,
Ardent,
Fetal hemoglobin,
Treatment,
Private Securities Litigation Reform Act,
COVID-19,
Interim,
Lists of diseases,
Administration,
IND,
Clinical trial,
PDE9,
Population,
Iron overload,
Webcast,
Investor,
Common,
Program,
Society,
Patient,
Volatile organic compound,
Therapy,
Nasdaq,
American Heart Association,
ASH,
Security (finance),
Investigational New Drug,
Transfusion-dependent anemia,
Disease,
Addition,
GLOBE,
Annual report,
ID,
Heart failure,
Investment,
FDA,
Forte,
Safety,
Hemoglobinopathy,
Company,
Pharmaceutical industry,
Heart failure with preserved ejection fraction,
NFE2L2,
Imara We look forward to engaging the FDA again after our upcoming Ardent interim analysis on a registration path for tovinontrine.
Key Points:
- We look forward to engaging the FDA again after our upcoming Ardent interim analysis on a registration path for tovinontrine.
- We hope to build upon these promising results in our interim analysis, which we expect will occur in the first week of April.
- We anticipate that these datasets will include safety, biomarker data, and for patients in the transfusion-dependent cohort, data on transfusion burden.
- ET to discuss its full year 2021 financial results and other business updates.
Thalassemia,
Patient,
ID,
Investor,
Heart failure,
Lists of diseases,
Webcast,
Hemoglobinopathy,
PDE9,
Sickle cell disease,
Review,
Nasdaq,
Heart failure with preserved ejection fraction,
GLOBE,
Therapy,
Pharmaceutical industry,
Imara,
NFE2L2 ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights.
Key Points:
- ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights.
- A live webcast will be available under Events and Presentations in the Investors section of the company's website .
- The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800-3873 (international) and referring to conference ID 5889355.
- A replay of the webcast will be archived on the Imara website following the presentation.
Retrieved on:
Thursday, February 10, 2022
Hemoglobinopathy,
Heart failure,
GLOBE,
Fireside,
PDE9,
Nasdaq,
Heart failure with preserved ejection fraction,
Sickle cell disease,
Patient,
Lists of diseases,
Imara,
Thalassemia,
Conference,
Therapy,
Pharmaceutical industry,
NFE2L2 BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m.
Key Points:
- BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m.
- ET.
- Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases.
- Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2related factor 2, or Nrf2.
Retrieved on:
Tuesday, January 25, 2022
BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for tovinontrine (IMR-687) to commence clinical development for the treatment of heart failure with preserved ejection fraction (HFpEF). Imara plans to initiate a Phase 2 trial in the second quarter of 2022 to evaluate tovinontrine in patients 45 years of age or older with persistent HFpEF symptoms.
Key Points:
- Imara plans to initiate a Phase 2 trial in the second quarter of 2022 to evaluate tovinontrine in patients 45 years of age or older with persistent HFpEF symptoms.
- Heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure, is typically caused by abnormalities of cardiac filling, which leads to symptoms such as shortness of breath, exercise intolerance and fluid retention.
- HFpEF is the most common form of heart failure; hospitalization rates are similar to heart failure with reduced ejection fraction (HFrEF, or systolic heart failure), but with fewer treatment options to improve symptoms and outcomes.
- Imara is advancing tovinontrine (IMR-687), a highly selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment currently in clinical development for sickle cell disease, beta-thalassemia and heart failure with preserved ejection fraction (HFpEF).
Retrieved on:
Wednesday, January 5, 2022
Lists of diseases,
Sickle cell disease,
Event-driven architecture,
Therapy,
Investor,
Patient,
Heart failure with preserved ejection fraction,
PDE9,
Thalassemia,
Conference,
Heart failure,
GLOBE,
Nasdaq,
Pharmaceutical industry,
NFE2L2 BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 1013, 2022.
Key Points:
- BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 1013, 2022.
- A webcast of the pre-recorded presentation will be made available at 7:00 AM ET on Monday, January 10th and will be available under "Events and Presentations" in the Investors section of the company's website at www.imaratx.com .
- Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases.
- Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2related factor 2, or Nrf2.
Retrieved on:
Tuesday, December 14, 2021
Fetal hemoglobin,
HBF,
Thalassemia,
U.S. Securities and Exchange Commission,
Heart failure,
Company,
Sickle cell disease,
Tumor necrosis factor,
Oxidative stress,
PDE9,
RBC,
Private Securities Litigation Reform Act,
Nasdaq,
Hemolysis,
Hemoglobinopathy,
COVID-19,
Iron overload,
Volatile organic compound,
PAH,
Pediatrics,
VOC,
Research,
Goal,
Inflammation,
Patient,
NF,
Lists of diseases,
Focal segmental glomerulosclerosis,
Therapy,
Security (finance),
FSGS,
Nucleated red blood cell,
Hypertensive emergency,
Program,
Erythropoiesis,
Augusta University,
GLOBE,
ASH,
Heart failure with preserved ejection fraction,
SCD,
Mouse,
Society,
Complexa,
Vaccine,
Pharmaceutical industry,
Palladium,
NFE2L2,
Townes,
HB BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced the presentation of data from its nuclear factor erythroid 2-related factor 2 (Nrf2) activator program, IMR-261, at the American Society of Hematology (ASH) Annual Meeting, held December 11-14, 2021.
Key Points:
- Preclinical studies evaluated the impact of IMR-261 using in-vitro cell cultures and in-vivo mouse models of sickle cell disease (SCD) and beta-thalassemia.
- Furthermore, an approximately 3-fold increase in F-cells was seen in both high dose and low dose groups when compared to placebo.
- We are pleased to report robust data with IMR-261 in validated preclinical models of SCD and beta-thalassemia, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- In preclinical sickle cell disease models, IMR-261 significantly increased HbF and F-cells, improved hemolytic markers, and decreased vaso-occlusive crises.
Retrieved on:
Monday, December 13, 2021
HBF,
U.S. Securities and Exchange Commission,
Fetal hemoglobin,
Heart failure,
FDA,
Vital signs,
Ardent,
Development,
OLE,
Company,
Sickle cell disease,
PDE9,
Clinical trial,
Private Securities Litigation Reform Act,
Forte,
Nasdaq,
COVID-19,
University,
Volatile organic compound,
VOC,
High,
Hydroxycarbamide,
White blood cell,
Safety,
Goal,
Patient,
CGMP,
Lists of diseases,
Therapy,
Security (finance),
Associate,
Red blood cell,
Thalassemia,
GLOBE,
ASH,
WBC,
Wireless ambulatory ECG,
Heart failure with preserved ejection fraction,
SCD,
University of Connecticut Health Center,
Society,
Pharmaceutical industry,
NFE2L2,
Imara These 12-month OLE data highlight the potential for tovinontrine to have longer term impact on VOC reductions.
Key Points:
- These 12-month OLE data highlight the potential for tovinontrine to have longer term impact on VOC reductions.
- Were happy to be closing out 2021 by sharing positive 12-month VOC data for tovinontrine as a potential candidate to treat sickle cell disease, said Dr. Ballal.
- In addition to the 12-month OLE data, Imara also reported preclinical data studying the effects of tovinontrine in beta-thalassemia mouse models.
- The preclinical results showed tovinontrine improved markers of beta-thalassemia, including an increase in total hemoglobin and red blood cell count.
